NORCROSS, Ga., Nov. 05, 2019 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained in subsequent ad hoc analysis of Galectin Therapeutics’ NASH-CX Phase 2 Clinical Trial, by investigators at the University of Indiana, has been accepted for a poster presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston on November 8-12, 2019. The poster presentation is titled “Enhanced liver fibrosis (ELF) score significantly predicts 52-week liver decompensation in patients with compensated NASH cirrhosis” authored by Eduardo Vilar-Gomez, Naga Chalasani, et al.

The poster itself will be released in accordance with AASLD’s policies.

Poster Session Date: Saturday, November 9, 2019
Poster Session Time: 2:00 PM – 7:00 PM
Hynes Convention Center, Hall B
“Enhanced liver fibrosis (ELF) score significantly predicts 52-week liver decompensation in patients with compensated NASH cirrhosis.” E. Vilar-Gomez. Abstract #1207

About the NASH-CX Phase 2b Trial

Galectin Therapeutics announced top-line results from its NASH-CX Phase 2 trial in December 2017. The Company is proceeding with plans for its NASH-RX Phase 3 clinical trial program with its galectin-3 inhibitor belapectin (GR-MD-02) in NASH cirrhosis. Plans for the NASH-RX trial were put forward in August via a Type C Written Response Only submission to the U.S. Food and Drug Administration (FDA) with the goal of finalizing the protocol and initiating the clinical trial in the near future.

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company‘s unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin (GR-MD-02) will lead to the first therapy for the treatment of fatty liver disease with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin; manufacturing of drug product now in scale-up may not be successful or meet regulatory expectations, the Company’s Phase 3 clinical trial for the treatment of fatty liver disease, now in the planning stages, and any future clinical studies, including those in connection with cancer immunotherapy may not proceed and may not produce positive results in a timely fashion, if at all, and could prove time-consuming and costly; plans regarding development, approval, and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.

Investor :
Galectin Therapeutics, Inc.
Jack Callicutt, Chief Financial Officer

Media :
Gregory FCA
Rachel Giltz, Senior Account Executive